Drug Profile
MicroRNA encapsulated nanocells - EnGeneIC
Alternative Names: EGFREDVmiR-16; MicroRNA packaged EDVTM nanocells - EnGeneIC; TargomiR; TargomiRs - EnGeneICLatest Information Update: 08 Sep 2017
Price :
$50
*
At a glance
- Originator EnGeneIC
- Developer Asbestos Diseases Research Institute; EnGeneIC; University of Sydney
- Class Antineoplastics; Cell therapies; MicroRNAs
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Mesothelioma
Most Recent Events
- 05 Sep 2017 Updated efficacy and adverse events data from the phase I/IIa MesomiR 1 trial in Mesothelioma released by EnGeneIC
- 27 Mar 2017 Phase-I/II development for Mesothelioma (Late-stage disease, Second-line therapy or greater) is ongoing in Australia (IV)
- 01 Jan 2017 EnGeneIC completes a phase I/II trial for Mesothelioma (Late-stage disease, Second-line therapy or greater) in Australia (IV) (NCT02369198)